Glucagon and diabetes

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We have considered the evidence, first that the presence of glucagon is essential in the pathogenesis of the full syndrome that results from complete insulin deficiency; second, that in the diabetic in whom insulin levels are relatively fixed, a rise in glucagon concentration contributes to endogenous hyperglycemia; and, third, that conventional methods of treatment of diabetes do not fully correct either the abnormal glucagon levels or the hyperglycemia, but when insulin therapy is supplemented with somatostatin, an agent which suppresses both glucagon and growth hormone, both hyperglycemia and hyperglucagonemia are corrected. These facts may one day provide a rationale for therapeutic efforts to suppress excess glucagon secretion in the management of diabetes in man.

Original languageEnglish (US)
Pages (from-to)713-722
Number of pages10
JournalMedical Clinics of North America
Volume62
Issue number4
StatePublished - 1978

Fingerprint

Glucagon
Hyperglycemia
Insulin
Somatostatin
Growth Hormone
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Glucagon and diabetes. / Raskin, Philip; Unger, Roger H.

In: Medical Clinics of North America, Vol. 62, No. 4, 1978, p. 713-722.

Research output: Contribution to journalArticle

@article{d1ea968183fd4ad085312ac954b97a43,
title = "Glucagon and diabetes",
abstract = "We have considered the evidence, first that the presence of glucagon is essential in the pathogenesis of the full syndrome that results from complete insulin deficiency; second, that in the diabetic in whom insulin levels are relatively fixed, a rise in glucagon concentration contributes to endogenous hyperglycemia; and, third, that conventional methods of treatment of diabetes do not fully correct either the abnormal glucagon levels or the hyperglycemia, but when insulin therapy is supplemented with somatostatin, an agent which suppresses both glucagon and growth hormone, both hyperglycemia and hyperglucagonemia are corrected. These facts may one day provide a rationale for therapeutic efforts to suppress excess glucagon secretion in the management of diabetes in man.",
author = "Philip Raskin and Unger, {Roger H}",
year = "1978",
language = "English (US)",
volume = "62",
pages = "713--722",
journal = "Medical Clinics of North America",
issn = "0025-7125",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Glucagon and diabetes

AU - Raskin, Philip

AU - Unger, Roger H

PY - 1978

Y1 - 1978

N2 - We have considered the evidence, first that the presence of glucagon is essential in the pathogenesis of the full syndrome that results from complete insulin deficiency; second, that in the diabetic in whom insulin levels are relatively fixed, a rise in glucagon concentration contributes to endogenous hyperglycemia; and, third, that conventional methods of treatment of diabetes do not fully correct either the abnormal glucagon levels or the hyperglycemia, but when insulin therapy is supplemented with somatostatin, an agent which suppresses both glucagon and growth hormone, both hyperglycemia and hyperglucagonemia are corrected. These facts may one day provide a rationale for therapeutic efforts to suppress excess glucagon secretion in the management of diabetes in man.

AB - We have considered the evidence, first that the presence of glucagon is essential in the pathogenesis of the full syndrome that results from complete insulin deficiency; second, that in the diabetic in whom insulin levels are relatively fixed, a rise in glucagon concentration contributes to endogenous hyperglycemia; and, third, that conventional methods of treatment of diabetes do not fully correct either the abnormal glucagon levels or the hyperglycemia, but when insulin therapy is supplemented with somatostatin, an agent which suppresses both glucagon and growth hormone, both hyperglycemia and hyperglucagonemia are corrected. These facts may one day provide a rationale for therapeutic efforts to suppress excess glucagon secretion in the management of diabetes in man.

UR - http://www.scopus.com/inward/record.url?scp=0018187887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018187887&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 713

EP - 722

JO - Medical Clinics of North America

JF - Medical Clinics of North America

SN - 0025-7125

IS - 4

ER -